← All trials
NCT05298332
Phase 1Interventional
Includes initial studies to determine the metabolism and pharmacologic actions of drugs in humans, the side effects associated with increasing doses, and to gain early evidence of effectiveness; may include healthy participants and/or patients.
View on ClinicalTrials.gov ↗Timeline
- Start date
- Mar 29, 2022
- Primary completion
- Aug 22, 2022
- Completion date
- Aug 22, 2022
- First posted
- Mar 28, 2022
- Last posted
- Nov 18, 2022
- Enrollment
- 37
- Arms / groups
- 3 / —
- Source
- AACT · ctgov ingestion
Sponsors
- Antios Therapeutics, IncLead sponsor
Drugs studied
Indications studied
CDEK-curated fields only — the ClinicalTrials.gov results mirror (baseline measures, adverse events, participant flow) is a separate, currently-dormant pipeline; see MIGRATION_PLAN.md.